LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 217.92% | 195.29% | 137.43% | 76.16% | 74.28% |
| Total Depreciation and Amortization | 61.96% | 40.11% | 31.32% | 7.16% | 16.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -145.20% | -147.70% | -130.28% | 1.26% | 2.10% |
| Change in Net Operating Assets | 89.14% | 70.75% | 47.41% | -10.32% | -193.40% |
| Cash from Operations | 151.10% | 116.53% | 76.43% | 77.88% | 42.05% |
| Capital Expenditure | 45.49% | -33.97% | -145.32% | -3,354.13% | -2,009.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 46.56% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -354.14% | -462.94% | -584.73% | -161.38% | -135.58% |
| Cash from Investing | -14.09% | -370.11% | -613.75% | -1,344.40% | -1,114.13% |
| Total Debt Issued | 220.72% | 109.63% | 95.36% | -40.26% | 22.36% |
| Total Debt Repaid | -111.88% | -212.75% | -41.88% | -12.36% | 20.09% |
| Issuance of Common Stock | -86.80% | 214.61% | -13.03% | -13.03% | -31.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -105.96% | -307.08% | -16.98% | 77.87% | 63.88% |
| Cash from Financing | 11.77% | 79.57% | 14.40% | -18.04% | 4.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,036.14% | 421.28% | 18,772.73% | 261.00% | -173.64% |